2021
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
Lewis R, Bewersdorf JP, Zeidan AM. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management And Research 2021, 13: 645-657. PMID: 33531837, PMCID: PMC7846829, DOI: 10.2147/cmar.s240600.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLower-risk myelodysplastic syndromesErythropoiesis-stimulating agentsTherapeutic optionsSymptomatic anemiaMyelodysplastic syndromeRed blood cell transfusionFurther therapeutic optionsBlood cell transfusionAvailable therapeutic optionsMajority of patientsManagement of anemiaPrimary clinical goalQuality of lifeResultant cytopeniasCell transfusionFrequent transfusionsImmunosuppressive therapyClinical improvementMost patientsSelect patientsTransfusion burdenClinical managementIron overloadNovel agentsAdditional therapeutics
2019
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
Bewersdorf JP, Zeidan AM. Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia 2019, 33: 1303-1312. PMID: 30962581, DOI: 10.1038/s41375-019-0448-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsErythropoiesis stimulating agentsMyelodysplastic syndromeGrowth factorIneffective erythropoiesisLower-risk myelodysplastic syndromesTGF-β pathway inhibitorLR-MDS patientsFurther therapeutic optionsRisk myelodysplastic syndromesLimited therapy optionsTGF-β receptor activationPromising therapeutic approachPhysiologic conditionsTGF-β pathwayAberrant TGFImmunomodulator lenalidomideLR-MDSMyelosuppressive effectsTherapeutic optionsTherapy optionsLife impairmentAdditional potential targetsClinical dataMDS pathogenesisTherapeutic approaches